BioCorRx Inc. (BICX)

[DREAM BIG]

News !!

BioCorRX Inc. Positions Itself Through New Acquisitions, And Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S.: Analyst Report Issued by Small Cap IR

Mar 27, 2015 07:00:00 (ET)


NEW YORK, March 27, 2015 /PRNewswire/ -- BioCorRx, Inc. (OTCBB: BICX) operating in Santa Ana, California is a healthcare solutions organization, which focuses solely on addiction treatment; the market for which is estimated at $22 billion in the U.S. alone. The Company utilizes a unique treatment regiment through the use of FDA-approved Naltrexone, which the Company has exclusive rights to (excluding Australia and New Zealand). This program is also supplemented with heavy life coaching in which patients receive further treatment for their alcohol or substance abuse addictions.

The Company has several strategic partnerships in the pipelines in which it hopes to increase its assets by issuing a letter of understanding to acquire Trinity RX Solutions (creator of Naltrexone) and all of its formulas. The Company has exclusive perpetual rights to the implant, however is in the process of obtaining it outright. Through licensing of its Start Fresh Program the Company has also begun to plan out introducing the program in to wellness centers across America. The pilot program will be introduced to five wellness centers, and upon successful completion will be made available to Myriad Medical Marketing's network of over 1000 medical centers nation wide.

For a more in-depth look at BioCorRx Inc. with an analyst brief and recommendation please follow the link below. There is no cost obligation to view the analyst brief and recommendation.

http://bit.ly/-BICX-AnalystReport

Copy and paste to browser may be required.

About Small Cap IR

We make the connection between sophisticated investors and high quality small cap companies. An issuer of reports written by chartered financial analysts (CFA's) who provide a straightforward assessment of the profiled company and have pledged to remain free of influence when writing research reports. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

For more information and services provided beyond this release please use contact information provided below.

Forward-Looking Disclaimer

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.

Compliance Procedure

Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.

A full disclaimer can be found by viewing the analyst report.

If you wish to have a company covered in more detail by our team, or wish to learn more about our services, please contact us at [e-mail]. For any urgent concerns or inquiries please contact us at [e-mail].

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

Contact: [e-mail]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocorrx-inc-positions-itself-through-new-acquisitions-and-strategic-partnerships-to-gain-market-share-of-the-22-billion-substance-abuse-treatment-market-in-the-us-analyst-report-issued-by-small-cap-ir-300056860.html

SOURCE Small Cap IR

/Web site: http://smallcapir.com


(END) Dow Jones Newswires

March 27, 2015 07:00 ET (11:00 GMT)